King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.